Molecule discovery specialist X-Chem, proclaimed a remarkable extension of their present drug discovery collaboration with AstraZeneca. The agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing for in-house screening of DNA-encoded libraries at AstraZeneca. As per the terms of the agreement, X-Chem will seek upfront technology access and license fees. This is the third agreement till date leading to numerous licenses to novel small molecules across multiple delivery programs.
Dr. Menelas Pangalos, Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit said “The DEX platform is an important pillar of our small molecule discovery strategy. This extended collaboration reflects the strength and success of our work with X-Chem over the past five years and secures long-term access to this capability.”